Munich - Delayed Quote EUR

Aelis Farma SA (69O.MU)

1.1950

0.0000

(0.00%)

At close: May 9 at 8:03:09 AM GMT+2

Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures

BORDEAUX, France, May 06, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Tuesday, May 27, 2025, at 2 p.m., at 1 rue Lafaurie de Monbadon, 33000 Bordeaux.

Business Wire 4 days ago

AELIS.PA
Aelis Farma: Availability of the 2024 Universal Registration Document

BORDEAUX, France, April 29, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces the publication of its 2024 Universal Registration Document (URD) as filed with the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 28, 2025, under number D.25-0314.

Business Wire 11 days ago

AELIS.PA
European Penny Stocks To Watch In April 2025

The European market has recently experienced significant volatility due to higher-than-expected U.S. trade tariffs, leading to sharp declines across major stock indexes such as the STOXX Europe 600 and Germany’s DAX. Amidst this uncertainty, investors may find opportunities in lesser-known corners of the market like penny stocks, which often represent smaller or newer companies with potential for growth at lower price points. While the term 'penny stock' might seem outdated, these investments...

Simply Wall St. 29 days ago

KGAUF

AELIS.PA

COM.MC
Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook

BORDEAUX, France, April 01, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its full year results for the year ended December 31, 2024.

Business Wire last month

AELIS.PA
Aelis Farma Announces the Final Analysis of the Landmark Phase 2B Clinical Trial in Cannabis Use Disorder (CUD) with the CB1-SSi AEF0117

BORDEAUX, France, March 26, 2025--Regulatory News: Two videoconferences will be held tomorrow, March 27, 2025in French at 05:30pm CET and in English at 07:30pm CET (02:30pm ET)

Business Wire last month

AELIS.PA
European Penny Stocks To Watch In March 2025

The European market has recently experienced a mix of gains and losses, with the pan-European STOXX Europe 600 Index snapping a streak of ten consecutive weeks of growth amid uncertainties surrounding U.S. trade policies. Despite these challenges, the potential for increased spending on defense and infrastructure by Germany and the EU offers some optimism for investors. Although "penny stocks" might seem like an outdated term, they still represent an intriguing investment area, particularly...

Simply Wall St. last month

MRX.DE

V6C.DE

AELIS.PA
Aelis Farma Announces Its 2025 Financial Calendar

BORDEAUX, France, February 17, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its indicative financial calendar for the financial year 2025.

Business Wire 2 months ago

AELIS.PA
Spotlight On January 2025's Promising Penny Stocks

As global markets experience a boost from easing core U.S. inflation and robust bank earnings, investors are keenly observing shifts in market dynamics. With value stocks outpacing growth shares and financials showing strong gains, the current landscape offers intriguing opportunities for discerning investors. Though the term 'penny stock' might sound like a relic of past trading days, it still points to relevant opportunities in smaller or newer companies that can lead to significant returns...

Simply Wall St. 3 months ago

LOKO.OL

1027.HK

AELIS.PA
Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome

BORDEAUX, France, November 18, 2024--Regulatory News: Two videoconferences will be held tomorrow, on Tuesday November 19, 2024, the first in French at 10:00 am CET and the second in English at 4:00 pm CET / 10:00 am ET.

Business Wire 5 months ago

AELIS.PA
Aelis Farma: Availability of the 2024 Half-year Financial Report

BORDEAUX, France, September 26, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 - ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year financial report has been made available to the public and filled with the French Financial Markets Authority (Autorité des marchés financiers).

Business Wire 7 months ago

AELIS.PA
Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update

BORDEAUX, France, September 25, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its results for the first half of 2024 and provides an update on its development.

Business Wire 7 months ago

AELIS.PA
Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)

BORDEAUX, France, September 04, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces results from the clinical Phase 2B trial conducted by Aelis Farma with AEF01171, evaluating its efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD) that used cannabis ≥5 days/week at baseline. In this study populatio

Business Wire 8 months ago

AELIS.PA
Aelis Farma: Availability of the Description of the Share Buyback Program

BORDEAUX, France, June 24, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces that the availability of the description of the share buyback program authorized by the Annual General Meeting of June 4, 2024.

Business Wire 10 months ago

AELIS.PA
Results of Aelis Farma Combined General Meeting of June 4, 2024

BORDEAUX, France, June 04, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases announces that all the resolutions recommended by the Board of directors were adopted by the Combined General Meeting of shareholders.

Business Wire 10 months ago

AELIS.PA
Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures

BORDEAUX, France, May 14, 2024--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, informs its shareholders and the financial community that the Company’s Combined General Meeting will be held on Tuesday, June 4, 2024, at 2 p.m., at 1 rue Lafaurie de Mondabon, 33000 Bordeaux.

Business Wire 11 months ago

AELIS.PA

Performance Overview

Return	69O.MU	CAC 40 (^FCHI)
YTD	-39.65%	+4.92%
1-Year	-90.95%	-5.42%
3-Year	-90.62%	+27.24%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aelis Farma SA (69O.MU)

Aelis Farma: Combined General Meeting of May 27, 2025: Availability of Preparatory Documents and Participation and Voting Procedures

Aelis Farma: Availability of the 2024 Universal Registration Document

European Penny Stocks To Watch In April 2025

Aelis Farma Reports Its 2024 Annual Financial Results and Confirms Its 2025 Outlook

Aelis Farma Announces the Final Analysis of the Landmark Phase 2B Clinical Trial in Cannabis Use Disorder (CUD) with the CB1-SSi AEF0117

European Penny Stocks To Watch In March 2025

Aelis Farma Announces Its 2025 Financial Calendar

Spotlight On January 2025's Promising Penny Stocks

Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome

Aelis Farma: Availability of the 2024 Half-year Financial Report

Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update

Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)

Aelis Farma: Availability of the Description of the Share Buyback Program

Results of Aelis Farma Combined General Meeting of June 4, 2024

Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures

Performance Overview